[PDF] Top 20 Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients.
Has 10000 "Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients." found on our website. Below are the top 20 most common "Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients.".
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients.
... Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy characterized by the t(9;22) chromosomal translocation that generates the BCR/ABL oncogene ...remission in CML ... See full document
13
Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.
... including myeloid derived suppressor cells (MDSCs), able to inhibit T cells ...population in chronic myeloid leukemia (CML) patients at diagnosis that decreased to ... See full document
10
Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis
... precursor cells (EPCs), activated circulating endothelial cells (aCECs), and mature circulating endothelial cells (mCECs) using four-color multiparametric flow cytometry in the peripheral ... See full document
6
Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.
... choice in chronic myeloid leukemia ...treated patients were able to discontinue therapy without disease ...IFN-a in CML patients in prolonged remission and isolate ... See full document
12
Detection of mutator phenotype in Brazilian patients with acute and chronic myeloid leukemia
... mutations in the primer- binding site of one or both alleles could result in allele am- plification failure or even the finding of null ...MSI in that patient may be due to some enzymatic overlap to ... See full document
6
J. Bras. Patol. Med. Lab. vol.53 número3
... Introduction: Chronic myeloid leukemia (CML) is a genetic disorder of hematopoietic stem cells, resulting in a myeloproliferative expansion of blood ...parameters in ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... monitored in 80 patients with acute lymphoid (ALL, n=44) or myeloid (AML, n=36) leukemia, undergoing allogeneic haemopoietic stem cell ...positive in 45% and the CI of ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... Acute Myeloid Leukaemia (AML), when compared to younger patients with the same disease, have a poor prognosis and represent a discrete population in terms of disease biology, treatment-related ... See full document
5
BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.
... pathway in the signaling transduction by BCR-ABL, we tested whether treatment with MEK inhibitor UO126 could rescue PTEN levels of ...shown in Figure 1D, UO126 restores normal PTEN levels in BCR-ABL ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.35 número2
... (FDA) in 1999. After only a few years, IM became a revolutionary molecule in the treatment of chronic myeloid leukemia ...CML patients who had not previously reached accelerated ... See full document
6
Gold nanoparticles for nanotheranostics in leukemia – Addressing Chronic Myeloid Leukemia
... particularly leukemia, show their potential as targets of smart nanomaterials and how much these diseases would benefit from a more personalized approach than current diagnostics and treatment ...foremost, ... See full document
220
Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
... vary in their effects on the sensitivity to standard doses and dose escalations of imatinib and as well as to other TKIs [3,6–7,13,36– ...resistant patients were treated with imatinib dose escalation to ... See full document
9
ANALYSIS OF mRNA TRANSCRIPTS IN CHRONIC MYELOID LEUKEMIA PATIENTS
... established in this work provided excellent amplification of cDNA from BCR/ABL ...33 patients, 25 collected in the chronic phase and 13 in the accelerated phase of the ...disease. ... See full document
6
Mesenchymal stem cells from patients with chronic myeloid leukemia do not express BCR-ABL and have absence of chimerism after allogeneic bone marrow transplant
... sisted in small amounts in these ...microchimerism in pa- tients submitted to other conditioning regi- mens during more recent post-BMT periods and/or in other hematologic diseases, as de- ... See full document
11
Mesenchymal Stem Cells - Emphasis in Adipose Tissue
... accumulation in human adipose stem cells at concentrations from 200 mg/mL upward in less than a week and caused elevated levels of adipocyte differentiation markers (proliferator-activated ... See full document
12
Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center
... III-IV toxicities were less common in the reduced inten- sity group. This trial was stopped early due to a slow inclu- sion of patients. The authors concluded that reduced intensity conditioning had similar ... See full document
6
Clinics vol.70 número3
... presenting in hematopoietic tissues and other ...observed in leukemia and is associated with an unfavorable prognosis ...(21-23). Leukemia is a systemic disease that can cause generalized ... See full document
7
Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting ß-cell regeneration
... rapid in children and slow in adults (3) (Figure 1). In the later stage of disease there is little or no insulin secretion, as indicated by low or undetectable plasma levels of ...ß- cells as ... See full document
10
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... O transplante alogênico de célula-tronco hematopoética permane- ce como a única terapêutica com potencial terapêutico para a LMC in todas as fases da doença. Entretanto, os resultados com a utiliza- ção do ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.36 número1
... of this widely practiced procedure remain controversial and under discussion. First, it appears that the greatest benefit of antibiotic prophylaxis is restricted to patients who are expected to develop long and ... See full document
2
temas relacionados